98048-97-6

98048-97-6 structure

Name: Fosinopril
Chemical Name: fosinopril
CAS Number: 98048-97-6
Molecular Formula: C₃₀H₄₆NO₇P
Molecular Weight: 563.66300
Catalog: API Circulatory system medication Antihypertensive drug
Create Date: 2018-08-27 15:48:51
Modify Date: 2025-08-22 12:25:38
Fosinopril (SQ28555) is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value of 0.18 μM[1]. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2].

Name	fosinopril
Synonyms	fosenopril Staril Fosinopril MFCD00870759 Secorvas

Description	Fosinopril (SQ28555) is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value of 0.18 μM[1]. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE)
Target	IC50: 0.18 μM; Ki: 1.675 μM
In Vitro	Fosinopril (0, 1, 10, 33, 100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2[1]. Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2[1]. Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with a Ki value of 1.675 μM[2].
In Vivo	Fosinopril (orally; 4.67 mg/kg; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and against cardiac dysfunction and structural alteration[3]. Fosinopril (orally; 4.67 mg/kg; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model[3]. Animal Model: HF post-acute myocardial infarction (AMI) rat model (SPF-grade Sprague-Dawley (SD) rats, 265 ± 15 g) [3] Dosage: 4.67 mg/kg Administration: p.o.; 4 weeks Result: Against cardiac dysfunction and structural alteration and suppressed apoptosis.
References	[1]. Ondetti, M.A., Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation, 1988. 77(6 Pt 2): p. I74-8. [2]. Piepho, R.W., Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000. 57 Suppl 1: p. S3-7. [3]. Sharma, S., et al., The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999. 6(4): p. 181-9.

Density	1.173 g/cm3
Boiling Point	705.7ºC at 760 mmHg
Melting Point	149-153ºC
Molecular Formula	C₃₀H₄₆NO₇P
Molecular Weight	563.66300
Flash Point	380.6ºC
Exact Mass	563.30100
PSA	120.02000
LogP	6.05920
Index of Refraction	1.531
Water Solubility	Insoluble

HS Code	2942000000

HS Code	2942000000

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

98048-97-6	134845-41-3
88889-14-9	474382-67-7
1217513-43-3	474519-28-3
137590-32-0	474382-60-0
1217819-83-4	46348-61-2
2138537-29-6	114458-24-1
41107-97-5	2172110-99-3
1337693-88-5	537039-75-1
1446947-66-5	53474-02-5
2171439-42-0	2172527-94-3